Notice Regarding Differences Between Forecast and Actual Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 and Revision of Full-Year Earnings Forecast

Business Overview

For the second quarter from April 1, 2026 to September 30, 2026, actual results exceeded prior forecasts, recording net sales of 30,172 million yen, operating income of 2,178 million yen, ordinary income of 2,273 million yen, interim net income attributable to owners of parent of 1,666 million yen, and interim net income per share of 60.84 yen. Based on these results, we have revised upward our consolidated full-year earnings forecast to net sales of 70,000 million yen, operating income of 8,000 million yen, ordinary income of 8,200 million yen, net income attributable to owners of parent of 5,500 million yen, and net income per share of 200.82 yen. The main factors were strong performance in the measurement and weighing instruments business and the medical & healthcare devices business, together with contributions from U.S. tariff refunds and foreign exchange effects.

Outlook and Impact

By segment, semiconductor-related businesses were flat, measurement and weighing instruments contributed to growth, and medical & healthcare devices particularly increased their contribution. The assumed exchange rates are 1 USD = 150 yen and 1 Russian ruble = 1.9 yen; using these assumptions and the latest demand forecasts, we revised the full-year forecast. While attention should be paid to market environmental risks, the Company expects demand recovery to continue and anticipates maintaining factors supporting profit increases.